Novel lower-cost blood test for cancer screening in dogs validated in large clinical study by PetDx
Retrieved on:
Friday, February 9, 2024
SAN DIEGO, Feb. 9, 2024 /PRNewswire/ -- PetDx® – The Liquid Biopsy Company for Pets™ published a clinical validation study this week showing that its new OncoK9® Screen test has a high detection rate across seven predefined, clinically relevant cancer types that represent a large proportion of all cancers found in dogs and are often difficult to detect by physical exam alone due to their anatomic location and/or lack of specific clinical signs. These cancer types are often aggressive, requiring prompt intervention, and have typically been associated with improved outcomes when detected and treated early.
Key Points:
- By integrating cell-free DNA quantification and next-generation sequencing using a proprietary method, the new test can be performed faster and at lower cost than the company's flagship OncoK9® Dx test, allowing for broader access to blood-based cancer screening in dogs.
- These cancer types are often aggressive, requiring prompt intervention, and have typically been associated with improved outcomes when detected and treated early.
- "Previously published research has shown that only around 10% of cancer cases are currently detected in dogs prior to the onset of clinical signs.
- "The availability of comprehensively validated blood-based cancer detection tools that can be readily incorporated into preventive care protocols opens the door to the development of cancer screening guidelines for early cancer detection in dogs."